No Data
No Data
Warner Pharmaceuticals (688799.SH): Notice of approval of the marketing application for the API arginine ibuprofen
Warner Pharmaceuticals (688799.SH) announced that Hunan Warner Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, accepted...
Express News | Warner Pharmaceuticals: Subsidiary drug arginine ibuprofen approved for marketing
Warrant Pharmaceutical's Unit Gets Nod to Market Benidipine Hydrochloride
Hunan Warrant Pharmaceutical's (SHA:688799) unit, Hunan Warrant Pharmaceutical Chiral Drug, received approval from China's National Medical Products Administration to market raw drug ingredient benidi
Warner Pharmaceuticals (688799.SH): Benidipine hydrochloride API received approval notice for marketing application
Gelonghui, May 27丨Warner Pharmaceuticals (688799.SH) announced that its wholly-owned subsidiary Hunan Warner Pharmaceutical Co., Ltd. received the “Notice of Approval of the Marketing Application for Chemical Ingredients” of benidipine hydrochloride issued by the State Drug Administration and publicized it on the “Registration Information Disclosure of Active Pharmaceutical Ingredients, Pharmaceutical Excipients and Pharmaceutical Packaging Materials” platform of the China Drug Administration (CDE) Drug Evaluation Center (CDE). Benidipine hydrochloride is a calcium channel blocker, mainly used to treat essential hypertension and angina pectoris. Benidipine hydrochloride is combined with DHP binding sites in cell membrane voltage-dependent calcium channels to inhibit calcium ions
Warner Pharmaceuticals (688799.SH) plans to explore investment opportunities in the medical and health sector in markets such as China and Southeast Asia through funds
Warner Pharmaceuticals (688799.SH) announced that it plans to invest no more than RMB 40 million to pledge 17.9767% of the investment of Hainan Heyi Vision Private Equity Investment Fund Partnership (Limited Partnership) (“Heyi Vision”). According to reports, the fund is positioned as an early growth stage venture capital fund in the medical and health sector. It focuses on innovation and value investment in the fields of biotechnology, innovative drugs, medical services, and medical devices, and aims to invest in startups in the medical and health sector in markets such as China and Southeast Asia.
Express News | Warner Pharmaceuticals: Plans to subscribe for 17.9767% of Heyi Vision's investment of no more than 40 million yuan
No Data